Latigo Biotherapeutics, Inc. (LTGO) Key Metrics
LTGO key metrics, 2024–2025
Fiscal year ended December 31, 2025 · U.S. dollarsLTGO returns How much profit the business earns on the capital it uses.
Return on assets+45.7 pts
−221.9%
2025 · hover or tap a bar for each year
20242025
Asset turnover
0.00
2025 · hover or tap a bar for each year
20242025
LTGO per-share figures Results divided by the shares outstanding at year-end.
Revenue per share
$0.00
2025 · hover or tap a bar for each year
20242025
Earnings per share
−$1.81
2025 · hover or tap a bar for each year
20242025
Free cash flow per share
−$1.62
2025 · hover or tap a bar for each year
20242025
Book value per share
−$3.85
2025 · hover or tap a bar for each year
20242025
Shares outstanding0.0%
60.2M
2025 · hover or tap a bar for each year
20242025
LTGO financial health Debt, liquidity and how easily interest is covered.
Net debt−$51.5M
−$69.4M
2025 · hover or tap a bar for each year
20242025
Current ratio+173.0%
4.00
2025 · hover or tap a bar for each year
20242025
LTGO returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
LTGO debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
LTGO key metrics
2024–2025| 2025 | 2024 | |
|---|---|---|
| Per share | ||
| Revenue per share | $0.00 | $0.00 |
| Earnings per share | −$1.81 | −$1.02 |
| Operating cash flow per share | −$1.62 | −$0.85 |
| Free cash flow per share | −$1.62 | −$0.85 |
| Cash per share | $1.15 | $0.30 |
| Book value per share | −$3.85 | −$2.15 |
| Tangible book value per share | −$3.85 | −$2.15 |
| Capex per share | $0.00 | $0.00 |
| Shares outstanding | 60.2M | 60.2M |
| Change in shares outstanding | 0.0% | — |
| Returns & profitability | ||
| Return on assets (ROA) | −221.9% | −267.6% |
| Return on tangible assets | −144.6% | −267.6% |
| Financial health | ||
| Cash & short-term investments | $69.4M | $17.9M |
| Net debt | −$69.4M | −$17.9M |
| Current ratio | 4.00 | 1.47 |
| Quick ratio | 4.00 | 1.47 |
| Working capital | $55.4M | $6.7M |
| Invested capital | −$301.1M | −$147.5M |
| Tangible asset value | −$231.7M | −$129.6M |
| Net current asset value | −$233.4M | −$131.3M |
| Graham net-net per share | −$3.95 | −$2.24 |
| Capital allocation | ||
| Capex / depreciation | 0.55 | 0.30 |
| Efficiency | ||
| Asset turnover | 0.00 | 0.00 |
| Average payables | $6.0M | $7.1M |
| Intangibles / total assets | 0.0% | 0.0% |
Computed from LTGO's annual financial statements (latest annual report filed —) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
LTGO valuation and financial ratios
See the LTGO income statement, the LTGO chart for price history, or the LTGO stock overview for the latest quote and news.
LTGO key metrics FAQ
What is Latigo Biotherapeutics's current ratio?
Latigo Biotherapeutics's current ratio was 4.00 at the end of fiscal 2025: current assets were 4.00 times current liabilities.